Centro de Anatomia Patológica Germano de Sousa Coimbra Portugal

Coimbra Institute for Clinical and Biomedical Research Faculty of Medicine University of Coimbra Coimbra Portugal

Department of Cardiac Thoracic Vascular Sciences and Public Health University of Padova Padova Italy

Instituto de Histologia Faculdade de Medicina Universidade de Coimbra Coimbra Portugal

The Fingerland Department of Pathology Charles University Medical Faculty Hospital Hradec Kralove Czech Republic

Zobrazit více v PubMed

Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C et al (2023) Overall survival with Osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 389(2):137–47. https://doi.org/10.1056/NEJMoa2304594 PubMed DOI

Lu S, Zhang W, Wu L et al (2024) Neotorch investigators. perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 331(3):201–211. https://doi.org/10.1001/jama.2023.24735 PubMed DOI PMC

Saw SPL, Le X, Hendriks LEL, Remon J (2024) New treatment options for patients with oncogene-addicted non-small cell lung cancer focusing on EGFR-mutant tumors. Am Soc Clin Oncol Educ Book. 44(3):e432516. https://doi.org/10.1200/EDBK_432516 PubMed DOI

Frost N, Reck M (2024) Non-small cell lung cancer metastatic without oncogenic alterations. Am Soc Clin Oncol Educ Book. 44(3):e432524. https://doi.org/10.1200/EDBK_432524 PubMed DOI

Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 42(1):47–58. https://doi.org/10.1200/JCO.23.02005 PubMed DOI

Raghav KPS, Siena S, Takashima A et al (2023) Trastuzumab deruxtecan (T-DXd) in patients with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase II DESTINY-CRC02 study. J Clin Oncol. 41(Suppl 16):3501. https://doi.org/10.1200/JCO.2023.41.16_suppl.3501 DOI

Pathak PS, Chan G, Deming DA, Chee CE (2024) State-of-the-art management of colorectal cancer: treatment advances and innovation. Am Soc Clin Oncol Educ Book. 44(3):e438466. https://doi.org/10.1200/EDBK_438466 PubMed DOI

Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S et al (2024) Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study. J Clin Oncol. 42(22):2637–44. https://doi.org/10.1200/JCO.23.02728 PubMed DOI

Salawu A, Demicco E, Chung PW, Feeney J, Spickard E, Rathore R et al. Molecular residual disease (MRD) detection using bespoke circulating tumor DNA assays in localized soft tissue sarcoma (STS). J Clin Oncol. 2023;41(Suppl 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.11509

Palassini E, Pizzamiglio S, Palmerini E, Quagliuolo V, Broto JM, Grignani G et al. A phase III randomized trial of neoadjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): feasibility and activity of concurrent chemotherapy and radiation therapy. J Clin Oncol. 2023;41(Suppl 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.11506

Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H (2020) European Society of Pathology (ESP). The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Arch. 476(4):491–497. https://doi.org/10.1007/s00428-020-02757-0 PubMed DOI PMC